Skip to main content

Table 2 Patient baseline characteristics

From: Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials

Number

Study

Drugs, Doses (μg), Regimen, Device

No of patients

Age means (SD)

Male (%)

Current smoker (%)

Postbronchodilator FEV1, % Predicted (SD)

Moderate/severe COPD exacerbation in previous 12 months, n (%) 0

Moderate/severe COPD exacerbation in previous 12 months, n (%) 1

Moderate/severe COPD exacerbation in previous 12 months, n (%) ≥ 2

1

TRILOGY Singh, 2016

BDP/FOR/GLY (100/6/12.5) bid MDI

687

63.3 (7.9)

74

47

36.9 (8.4)

NA

NA

NA

BDP/FOR (100/6) bid MDI

680

63.8 (8.2)

77

47

36.2 (8.6)

NA

NA

NA

2

FULFIL Lipson,2017

FF/UMEC/VI (100/62.5/25) od DPI

911

64.2 (8.56)

74

44

45.5 (12.97)

34

28

38

BUD/FOR (400/12) bid DPI

899

63.7 (8.71)

74

44

45.1 (13.64)

35

28

37

3

IMPACT Lipson,2018

FF/UMEC/VI (100/62.5/25) od DPI

4151

65.3 (8.2)

67

35

45.7 (15.0)

 < 1

45

55

FF/VI (100/25) od DPI

4134

65.3 (8.3)

66

34

45.5 (14.8)

 < 1

46

54

UMEC/VI (62.5/25) od DPI

2070

65.2 (8.3)

66

35

45.4 (14.7)

 < 1

45

55

4

KRONOS Ferguson,2018

BUD/GLY/FOR (320/18/9.6) bid MDI

639

64.9 (7.8)

72

40.1

50.2 (14.3)

73.4

19.6

7

GLY/FOR (18/9.6) bid MDI

625

65.1 (7.7)

68.8

41.1

50.2 (13.8)

75.7

17.3

7

BUD/FOR (320/9.6) bid MDI

314

65.2 (7.2)

71.3

36.6

50 (14)

74.8

19.4

5.7

5

TRIBUTE Papi,2018

BDP/FOR/GLY (100/6/10) bid MDI

764

64.4 (7.7)

72

46

36.4 (8.0)

NA

80

20

IND/GLY (85/43) od DPI

768

64.5 (7.7)

72

43

36.4 (8.1)

NA

82

18

6

ETHOS Rabe,2020

BUD/GLY/FOR (320/18/9.6) bid MDI

2144

64.6 (7.6)

59

42.6

43.6 (10.3)

0.1

44

55.9

BUD/GLY/FOR (160/18/9.6) bid MDI

2124

64.6 (7.6)

61.2

40.8

43.1 (10.4)

0.1

43.9

56

BUD/FOR (320/9.6) bid MDI

2136

64.6 (7.6)

60

40.5

43.4 (10.4)

0.1

42.8

57.1

GLY/FOR (18/9.6) bid MDI

2125

64.8 (7.6)

58.7

40.4

43.5 (10.2)

0.1

42.8

57.1

  1. BDP/FOR/GLY: beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide; BUD/GLY/FOR: budesonide/glycopyrronium bromide/formoterol fumarate; FF/UMEC/VI: fluticasone furoate/umeclidinium/vilanterol; BDP/FOR: beclomethasone dipropionate/formoterol fumarate; BUD/FOR: budesonide/formoterol fumarate; UMEC/VI: umeclidinium bromide/vilanterol; GLY/FOR: glycopyrronium bromide/formoterol fumarate; IND/GLY: indacaterol/glycopyrronium bromide; OD: once daily; BID: twice daily; MDI: metered-dose inhaler formulation; DPI: dry powder inhaler formulation; SD: Standard deviation; NA: Not applicable